Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Tough-to-Treat bladder cancer

NCT ID NCT03898180

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or keep their cancer from growing. It included 505 people whose cancer had spread and who could not take the chemotherapy drug cisplatin. The trial was stopped early because an independent committee found the combination was not working better than pembrolizumab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

505 people

The number who actually took part.

Started

May 2019

Finished

May 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial carcinoma (UC) of the renal pelvis, ureter (upper urinary tract), bladder, or urethra. * Has ≥1 measurable target lesion per RECIST 1.1 as assessed by the local site investigator/radiologist. * Has provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated and adequate for Programmed Death-Ligand 1 (PD-L1) evaluation. * Has received no prior systemic chemotherapy for advanced or metastatic UC with the following exceptions: * Neoadjuvant (prior to surgery) platinum-based chemotherapy for treatment of muscle-invasive bladder cancer with recurrence \>12 months from completion of the therapy is permitted. * Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy, with recurrence \>12 months from completion of the therapy, is permitted. * Meets criteria for either option a or option b (below): * a. Has a tumor(s) with PD-L1 combined positive score (CPS) ≥10 and is considered ineligible to receive cisplatin-based combination therapy, based on 1 of the following: * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2 within 7 days prior to randomization * National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Grade ≥2 audiometric hearing loss * NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy OR * b. In the opinion of the investigator, is considered ineligible to receive any platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on: * ECOG PS of 2 within 7 days prior to randomization and ≥1 of the following: * Documented visceral metastatic disease * NCI CTCAE Version 4.0 Grade ≥2 audiometric hearing loss * NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy * Other reason for the participant's being unable to receive both cisplatin and carboplatin safely. Additional criteria for platinum ineligibility will be considered and allowed on a case-by-case basis, following consultation with the Sponsor. Note: Participants considered ineligible for any platinum-based chemotherapy are eligible for this study regardless of their tumor PD-L1 status. * Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a life expectancy of ≥3 months. * Male participants are eligible to participate if they agree to the following during the treatment period and for ≥30 days after the last dose of pembrolizumab or lenvatinib/placebo: * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR * Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause as detailed below: * Agrees to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. * A female participant is eligible to participate if she is not pregnant or breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive method that is highly effective (with a failure rate of \<1% per year) with low user dependency, or is abstinent from heterosexual intercourse as her preferred and usual lifestyle during the intervention period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/placebo. * Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg at screening and no change in antihypertensive medications within 1 week prior to randomization. * Has adequate organ function. Exclusion Criteria: * Has disease that is suitable for local therapy administered with curative intent (e.g. chemotherapy and radiation for Stage 3 disease). * Has tumor with any neuroendocrine or small cell component. * Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass, malabsorption) that, in the opinion of the investigator, may affect oral drug absorption. * Has had major surgery within 3 weeks prior to the first dose of study treatment * Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula. * Has radiographic evidence of major blood vessel invasion/infiltration, or has had clinically significant hemoptysis (≥0.5 teaspoon of bright red blood) or tumor bleeding within 2 weeks prior to the first dose of study treatment. * Has had significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of New York Heart Association (NYHA) \>Class II congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia associated with hemodynamic instability. * Has known intolerance or severe hypersensitivity (Grade ≥3) to pembrolizumab or lenvatinib or any of their excipients * Has received lenvatinib as monotherapy or in combination with a programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor or has previously been enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of the treatment received. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor, indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 \[CTLA-4\], OX 40, CD137), or any other antibody or drug targeting T-cell costimulatory pathways in the adjuvant or advanced/metastatic setting. * Has received prior radiotherapy to a metastatic site without the use of chemotherapy radiosensitization within 3 weeks of the first dose of study treatment, with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks before the start of study treatment. Participants must have recovered from all radiation-related toxicities, and must not require corticosteroids. * Has received a live vaccine within 30 days prior to the first dose of study treatment. * In the investigator's judgment, has not recovered from toxicity or other complications from any major surgery prior to starting study treatment. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent. * Has history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization. * Has had an active malignancy (except locally advanced or metastatic UC) within the past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded. * Has a history of prostate cancer (T2NXMX or lower with Gleason score ≤7) treated with definitive intent (surgically or with radiation therapy) ≥1 year prior to study entry is acceptable, provided that the participant is considered prostate cancer-free. * Has central nervous system (CNS) metastases, unless the participant has completed local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has discontinued use of corticosteroids for this indication for ≥4 weeks before starting study treatment. Any signs (e.g. radiologic) or symptoms of CNS metastases must be stable for ≥4 weeks before starting study treatment. * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with disease-modifying agents, corticosteroids, or immunosuppressive drugs). * Has a history of (non-infectious) pneumonitis that required systemic steroids, or current pneumonitis. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known history of or is positive for active hepatitis B virus (HBV) or has active hepatitis C virus (HCV). * Has active tuberculosis (TB). * Is receiving hemodialysis. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and lenvatinib/placebo. * Has had an allogeneic tissue/solid organ transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urothelial carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urothelial carcinoma

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda ( Site 0307)

    Milan, Lombardy, 20162, Italy

  • Aalborg Universitets Hospital ( Site 0684)

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus Universitets hospital ( Site 0683)

    Aarhus N, Central Jutland, 8200, Denmark

  • Akita University Hospital ( Site 0124)

    Akita, 010-8543, Japan

  • Amphia Ziekenhuis Breda ( Site 0331)

    Breda, North Brabant, 4819 EV, Netherlands

  • Ankara Sehir Hastanesi ( Site 0455)

    Ankara, 06800, Turkey (Türkiye)

  • Antalya Memorial Hospital Department of Medical Oncology ( Site 0461)

    Antalya, 07020, Turkey (Türkiye)

  • Assaf Harofeh Medical Center ( Site 0556)

    Ẕerifin, 70300, Israel

  • Assuta Ashdod Public ( Site 0562)

    Ashdod, 7747629, Israel

  • Austin Health-Austin Hospital ( Site 0154)

    Heidelberg, Victoria, 3084, Australia

  • Azienda Ospedaliera Santa Maria ( Site 0303)

    Terni, 05100, Italy

  • Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0305)

    Catania, 95126, Italy

  • Bacs-Kiskun Megyei Korhaz ( Site 0510)

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 0509)

    Budapest, 1106, Hungary

  • Banner MD Anderson Cancer Center ( Site 0016)

    Gilbert, Arizona, 85234, United States

  • Baylor Scott & White Medical Center - Temple ( Site 0706)

    Temple, Texas, 76508, United States

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce

    Miskolc, Borsod-Abauj Zemplen county, 3526, Hungary

  • CEMAIC ( Site 0581)

    Córdoba, X5008HHW, Argentina

  • CHD Vendee-onco-hematologie ( Site 0251)

    La Roche-sur-Yon, Vendee, 85925, France

  • CHIC Quimper ( Site 0245)

    Quimper, Finistere, 29107, France

  • CHU Poitiers ( Site 0253)

    Poitiers, Ain, 86021, France

  • CHU de Bordeaux- Hopital Saint Andre ( Site 0235)

    Bordeaux, Gironde, 33075, France

  • CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0104)

    Québec, Quebec, G1R 2J6, Canada

  • CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0102)

    Sherbrooke, Quebec, J1H5N4, Canada

  • Cancer Care Northwest ( Site 0009)

    Spokane, Washington, 99218, United States

  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0751)

    Ürümqi, Xinjiang, 830011, China

  • Central Clinical Hospital with Polyclinic ( Site 0415)

    Moscow, Moscow, 121359, Russia

  • Centre D Oncologie de Gentilly ( Site 0240)

    Nancy, Meurthe-et-Moselle, 54100, France

  • Centre Hospitalier de la Cote Basque ( Site 0239)

    Bayonne, Pyrenees-Atlantiques, 64109, France

  • Centre Leon Berard ( Site 0244)

    Lyon, Rhone, 69373, France

  • Centre Rene Gauducheau ICO ( Site 0250)

    Saint-Herblain, Loire-Atlantique, 44805, France

  • Centre de Cancerologie du Grand Montpellier ( Site 0249)

    Montpellier, Languedoc-Roussillon, 34070, France

  • Centro Medico Dra De Salvo ( Site 0593)

    Buenos Aires, C1426ANZ, Argentina

  • Centro Oncologico de Integracion Regional. COIR ( Site 0576)

    Mendoza, M5500AYB, Argentina

  • Centro Oncológico de Rosario ( Site 0584)

    Rosario, Santa Fe Province, S2000KZE, Argentina

  • Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0585)

    Viedma, Río Negro Province, R8500ACE, Argentina

  • Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0577)

    Berazategui, Buenos Aires, B1884BBF, Argentina

  • Centro de Urología CDU ( Site 0590)

    Buenos Aires, Buenos Aires F.D., C1120AAT, Argentina

  • Centro di Riferimento Oncologico CRO ( Site 0304)

    Aviano, Pordenone, 33081, Italy

  • Chiba Cancer Center ( Site 0127)

    Chiba, 260-8717, Japan

  • China Medical University Hospital ( Site 0213)

    Taichung, 40447, Taiwan

  • Chongqing Cancer Hospital ( Site 0741)

    Chongging, Chongqing Municipality, 400030, China

  • Chonnam National University Hwasun Hospital ( Site 0194)

    Hwasun Gun, Jeonranamdo, 58128, South Korea

  • Chungnam National University Hospital ( Site 0195)

    Daejeon, Taejon-Kwangyokshi, 35015, South Korea

  • Clinical Hospital Saint Luka ( Site 0421)

    Saint Petersburg, Sankt-Peterburg, 194044, Russia

  • Clinique Pasteur ( Site 0252)

    Tolouse, Haute-Garonne, 31076, France

  • Community Cancer Institute ( Site 0777)

    Clovis, California, 93611, United States

  • Comprehensive Cancer Centers of Nevada ( Site 0005)

    Las Vegas, Nevada, 89169, United States

  • Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0457)

    Adana, 01330, Turkey (Türkiye)

  • Derriford Hospital ( Site 0388)

    Plymouth, PL6 8DH, United Kingdom

  • Deventer Ziekenhuis ( Site 0341)

    Deventer, Overijssel, 7416 SE, Netherlands

  • Ege Universitesi Tulay Aktas Onkoloji Hastanesi ( Site 0462)

    Izmir, 35100, Turkey (Türkiye)

  • Ehime University Hospital ( Site 0137)

    Tōon, Ehime, 791-0295, Japan

  • Erasmus MC ( Site 0332)

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Europejskie Centrum Zdrowia Otwock ( Site 0532)

    Otwock, Masovian Voivodeship, 05-400, Poland

  • Fifth Medical Center of CPLA General Hospital ( Site 0732)

    Beijing, Beijing Municipality, 100071, China

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0301)

    Milan, 20133, Italy

  • Fudan University Shanghai Cancer Center ( Site 0721)

    Shanghai, Shanghai Municipality, 200032, China

  • GBUZ Leningrad Regional Clinical Oncology Dispensary ( Site 0426)

    Kuzmolovskiy Settlement, Leningradskaya Oblast', 188663, Russia

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0459)

    Istanbul, 34722, Turkey (Türkiye)

  • Ha Emek Medical Center ( Site 0560)

    Afula, 1834111, Israel

  • Hadassah Ein Kerem Medical Center ( Site 0558)

    Jerusalem, 9112001, Israel

  • Haga Ziekenhuis ( Site 0333)

    The Hague, South Holland, 2545 AA, Netherlands

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0101)

    Hamilton, Ontario, L8V 5C2, Canada

  • Harbin Medical University Cancer Hospital ( Site 0750)

    Harbin, Heilongjiang, 150081, China

  • Helios Kliniken Schwerin GmbH ( Site 0278)

    Schwerin, Mecklenburg-Vorpommern, 19049, Germany

  • Herlev Hospital ( Site 0681)

    Herlev, Capital Region, 2730, Denmark

  • Hirosaki University Hospital ( Site 0123)

    Hirosaki, Aomori, 036-8563, Japan

  • Hopital de la Timone ( Site 0246)

    Marseille, Bouches-du-Rhone, 13005, France

  • Hospital General Universitari Vall d Hebron ( Site 0358)

    Barcelona, 08035, Spain

  • Hospital Infanta Cristina ( Site 0355)

    Badajoz, 06080, Spain

  • Hospital La Princesa ( Site 0862)

    Madrid, 28006, Spain

  • Hospital Teresa Herrera - Chuac ( Site 0357)

    A Coruña, La Coruna, 15006, Spain

  • Hospital Universitario Gregorio Maranon ( Site 0352)

    Madrid, 28009, Spain

  • Hospital Universitario HM Sanchinarro ( Site 0356)

    Madrid, Madrid, Comunidad de, 28050, Spain

  • Hubei Cancer Hospital ( Site 0744)

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital ( Site 0745)

    Changsha, Hunan, 410013, China

  • ICO L Hospitalet ( Site 0361)

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 0378)

    London, London, City of, W6 8RF, United Kingdom

  • Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0351)

    Badalona, Barcelona, 08916, Spain

  • Institut Curie ( Site 0237)

    Paris, 75005, France

  • Institut Gustave Roussy ( Site 0243)

    Villejuif, Val-de-Marne, 94805, France

  • Institut de Cancerologie Strasbourg Europe ( Site 0232)

    Strasbourg, Alsace, 67033, France

  • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0236)

    Angers, Maine-et-Loire, 49055, France

  • Instituto Medico Alexander Fleming ( Site 0578)

    Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina

  • Instituto de Investigaciones Metabolicas ( Site 0589)

    Buenos Aires, C1012AAR, Argentina

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0454)

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Tumori Giovanni Paolo II ( Site 0306)

    Bari, 70124, Italy

  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0507)

    Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary

  • John Wayne Cancer Institute ( Site 0017)

    Santa Monica, California, 90404, United States

  • Joliet Oncology Hematology ( Site 0091)

    Joliet, Illinois, 60436, United States

  • Kaohsiung Chang Gung Memorial Hospital ( Site 0217)

    Kaohsiung City, 83301, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 0216)

    Kaoshiung, Kaohsiung, 807, Taiwan

  • Karmanos Cancer Institute ( Site 0712)

    Detroit, Michigan, 48201, United States

  • Kent and Canterbury Hospital ( Site 0390)

    Canterbury, Kent, CT1 3NG, United Kingdom

  • Kitasato University Hospital ( Site 0129)

    Sagamihara, Kanagawa, 252-0375, Japan

  • Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0271)

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Korea University Anam Hospital ( Site 0197)

    Seoul, 02841, South Korea

  • Lakeridge Health ( Site 0103)

    Oshawa, Ontario, L1G 2B9, Canada

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002)

    New York, New York, 10016, United States

  • Lister Hospital ( Site 0376)

    Stevenage, Hertfordshire, SG1 4AB, United Kingdom

  • Luxmed Onkologia sp. z o. o. ( Site 0541)

    Warsaw, Masovian Voivodeship, 01-748, Poland

  • Maastricht Universitair Medisch Centrum - MUMC ( Site 0334)

    Maastricht, Limburg, 6229 HX, Netherlands

  • Macquarie University ( Site 0151)

    North Ryde, New South Wales, 2109, Australia

  • Markusovszky Egyetemi Oktatokorhaz ( Site 0502)

    Szombathely, Vas County, 9400, Hungary

  • Mater Misericordiae Ltd ( Site 0158)

    South Brisbane, Queensland, 4101, Australia

  • Medical Hospital, Tokyo Medical And Dental University ( Site 0130)

    Tokyo, 113-8519, Japan

  • Medical Rehabilitation Center ( Site 0411)

    Moscow, Moscow, 125367, Russia

  • Medical University of South Carolina-Hollings Cancer Center ( Site 0029)

    Charleston, South Carolina, 29425, United States

  • Meir Medical Center ( Site 0554)

    Kfar Saba, 4428164, Israel

  • Mercy Hospital Saint Louis - David C. Pratt Cancer Center ( Site 0095)

    St Louis, Missouri, 63141, United States

  • Monash Health ( Site 0160)

    Clayton, Victoria, 3168, Australia

  • Murmansk Regional Oncology Dispensary ( Site 0420)

    Murmansk, Murmansk Oblast, 183057, Russia

  • Nagasaki University Hospital ( Site 0136)

    Nagasaki, 852-8501, Japan

  • Nanjing Drum Tower Hospital ( Site 0737)

    Nanjing, Jiangsu, 210008, China

  • Nara Medical University Hospital ( Site 0133)

    Kashihara, Nara, 634-8522, Japan

  • National Cancer Center ( Site 0196)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital East ( Site 0128)

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital ( Site 0215)

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital ( Site 0211)

    Taipei, 100, Taiwan

  • Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0456)

    Konya, 42080, Turkey (Türkiye)

  • New England Cancer Specialists ( Site 0047)

    Scarborough, Maine, 04074, United States

  • Northwest Georgia Oncology Centers PC ( Site 0707)

    Marietta, Georgia, 30060, United States

  • Nottingham University Hospital NHS Trust ( Site 0383)

    Nottingham, NG5 1PB, United Kingdom

  • Odense Universitetshospital ( Site 0682)

    Odense, Region Syddanmark, 5000, Denmark

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0774)

    Tulsa, Oklahoma, 74146, United States

  • Omsk Clinical Oncology Dispensary ( Site 0418)

    Omsk, Omsk Oblast, 644013, Russia

  • Orszagos Onkologiai Intezet ( Site 0503)

    Budapest, 1122, Hungary

  • Osaka City University Hospital ( Site 0132)

    Osaka, 545-8586, Japan

  • Ospedale Borgo Roma-Oncologia ( Site 0308)

    Verona, 37134, Italy

  • Ospedale San Raffaele-Oncologia Medica ( Site 0309)

    Milan, Lombardy, 20132, Italy

  • Peking University First Hospital ( Site 0726)

    Beijing, Beijing Municipality, 100034, China

  • Peking University Third Hospital ( Site 0727)

    Beijing, Beijing Municipality, 100089, China

  • Peninsula Health Frankston Hospital ( Site 0153)

    Frankston, Victoria, 3199, Australia

  • Policlinico S. Orsola - Malpighi (Bologna) ( Site 0302)

    Bologna, 40138, Italy

  • Queens Hospital-Purple Zone ( Site 0377)

    Romford, Essex, RM7 0AG, United Kingdom

  • Quincy Medical Group ( Site 0022)

    Quincy, Illinois, 62301, United States

  • Rabin Medical Center ( Site 0553)

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center ( Site 0552)

    Haifa, 3109601, Israel

  • Rigshospitalet ( Site 0680)

    Copenhagen, Capital Region, 2100, Denmark

  • Royal Preston Hospital ( Site 0379)

    Preston, Lancashire, PR2 9HT, United Kingdom

  • Royal Stoke University Hospital Univ. Hosps of North Midlands NHST ( Site 0392)

    Stoke-on-Trent, ST4 6QG, United Kingdom

  • Russian Scientific Center of Roentgenoradiology ( Site 0424)

    Moscow, Moscow, 117485, Russia

  • Saint Bartholomew s Hospital - London ( Site 0386)

    London, London, City of, EC1A 7BE, United Kingdom

  • Saitama Medical University International Medical Center ( Site 0125)

    Hidaka, Saitama, 350-1298, Japan

  • Sakarya Universitesi Tip Fakultesi Arastirma Hastanesi ( Site 0460)

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center ( Site 0193)

    Seoul, 06351, South Korea

  • Sapporo Medical University Hospital ( Site 0122)

    Sapporo, Hokkaido, 060-8543, Japan

  • Seattle Cancer Care Alliance ( Site 0003)

    Seattle, Washington, 98109, United States

  • Second Affiliated Hospital, Zhejiang University ( Site 0734)

    Hangzhou, Zhejiang, 310009, China

  • Seoul National University Hospital ( Site 0191)

    Seoul, 03080, South Korea

  • Severance Hospital ( Site 0192)

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 0559)

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0551)

    Ramat Gan, 5265601, Israel

  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0504)

    Kaposvár, 7400, Hungary

  • Sourasky Medical Center ( Site 0561)

    Tel Aviv, 6423906, Israel

  • St. Antonius Ziekenhuis ( Site 0335)

    Utrecht, 3543 AZ, Netherlands

  • St. Peter's Hospital Cancer Care Center ( Site 0042)

    Albany, New York, 12208, United States

  • Staedtisches Krankenhaus Kiel GmbH ( Site 0285)

    Kiel, Schleswig-Holstein, 24116, Germany

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 0746)

    Guangzhou, Guangdong, 510289, China

  • Sun Yat-Sen University Cancer Center ( Site 0752)

    Guangdong, Guangdong, 510060, China

  • Sunnybrook Research Institute ( Site 0106)

    Toronto, Ontario, M4N 3M5, Canada

  • Szpital Miejski im. Jana Pawła II w Bielsku-Białej ( Site 0542)

    Bielsko-Biala, Silesian Voivodeship, 43-300, Poland

  • Szpital Wojewodzki ( Site 1062)

    Tarnów, Lesser Poland Voivodeship, 33-100, Poland

  • Taichung Veterans General Hospital ( Site 0214)

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital ( Site 0212)

    Taipei, 11217, Taiwan

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0749)

    Guangzhou, Guangdong, 510230, China

  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0738)

    Xian, Shanxi, 710061, China

  • The First Affiliated Hospital of Xiamen University ( Site 0743)

    Xiamen, Fujian, 361003, China

  • Thomas Jefferson University Hospital ( Site 0051)

    Philadelphia, Pennsylvania, 19107, United States

  • Tokushima University Hospital ( Site 0134)

    Tokushima, 770-8503, Japan

  • Universitaetsklinikum Essen ( Site 0274)

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH ( Site 0284)

    Marburg, Hesse, 35032, Germany

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0282)

    Hamburg, 20246, Germany

  • Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0277)

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Universitaetsmedizin Goettingen ( Site 0281)

    Göttingen, Lower Saxony, 37075, Germany

  • University College London Hospital NHS Foundation Trust ( Site 0380)

    London, London, City of, NW1 2PG, United Kingdom

  • University of California Irvine Medical Center ( Site 0078)

    Orange, California, 92868, United States

  • University of Chicago ( Site 0039)

    Chicago, Illinois, 60637, United States

  • University of Tsukuba Hospital ( Site 0126)

    Tsukuba, Ibaraki, 305-8576, Japan

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 0535)

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • Urologica Praktyka Lekarska Adam Marcheluk ( Site 0543)

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • Uzsoki Utcai Korhaz ( Site 0508)

    Budapest, 1145, Hungary

  • Veterans Health Service Medical Center ( Site 0198)

    Seoul, 05368, South Korea

  • VieCuri Medisch Centrum ( Site 0340)

    Venlo, Limburg, 5912 BL, Netherlands

  • Virginia Cancer Institute ( Site 0099)

    Richmond, Virginia, 23230, United States

  • Volga District Medical Center Federal Medical and Biological Agency ( Site 0413)

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603074, Russia

  • Weston Park Hospital ( Site 0387)

    Sheffield, Derbyshire, S10 2SJ, United Kingdom

  • Xarxa Assistencial Universitaria Manresa ( Site 0354)

    Manresa, Barcelona, 08243, Spain

  • Yamaguchi University Hospital ( Site 0135)

    Ube, Yamaguchi, 755-8505, Japan

  • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0414)

    Yaroslavl, Yaroslavl Oblast, 150054, Russia

  • Zhejiang Provincial People's Hospital ( Site 0735)

    Hangzhou, Zhejiang, 310014, China

  • Zhongshan Hospital Fudan University ( Site 0725)

    Shanghai, Shanghai Municipality, 200032, China

  • Ziekenhuis Rijnstate ( Site 0342)

    Arnhem, Gelderland, 6815 AD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.